1-乙酰氨基-4-溴萘 | 91394-66-0

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-乙酰氨基-4-溴萘
• 英文名称: 1-(acetylamino)-4-bromonaphthalene
• 英文别名: N-(4-bromonaphthalen-1-yl)acetamide；4-Brom-1-acetamido-naphthalin；1-Acetamido-4-bromonaphthalene
• CAS: 91394-66-0
• 化学式: C₁₂H₁₀BrNO
• 分子量: 264.121
• InChiKey: KAVKNHPXAMTURG-UHFFFAOYSA-N

物化性质

• 熔点：
  160-163
• 沸点：
  454.3±28.0 °C(Predicted)
• 密度：
  1.528±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2924299090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Acetamido-4-bromonaphthalene
Synonyms: N-(4-Bromonaphthalen-1-yl)acetamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Acetamido-4-bromonaphthalene
CAS number: 91394-66-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H10BrNO
Molecular weight: 264.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-乙酰氨基-4-溴萘 在 氢氧化钾 作用下， 生成 1-溴代萘
  参考文献：
  名称：

  Rother, Chemische Berichte, 1871, vol. 4, p. 850

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙酰氨基-1-萘基磺酸 在 溴 作用下， 生成 1-乙酰氨基-4-溴萘
  参考文献：
  名称：

  Darstellung von azohomologen Farbstoffen mithöhererMolekulargrösse（II）

  摘要：

  DOI：

  10.1002/hlca.193301601110

文献信息

• MONNA, a Potent and Selective Blocker for Transmembrane Protein with Unknown Function 16/Anoctamin-1
  作者：Soo-Jin Oh、Seok Jin Hwang、Jonghoon Jung、Kuai Yu、Jeongyeon Kim、Jung Yoon Choi、H. Criss Hartzell、Eun Joo Roh、C. Justin Lee

  DOI：10.1124/mol.113.087502

  日期：2013.11

  Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established ([Oh et al., 2008][1]). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a −NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC50 < 10 μ M. The most potent blocker, N -((4-methoxy)-2-naphthyl)-5-nitroanthranilic acid (MONNA), had an IC50 of 0.08 μ M for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10∼30 μ M MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia. [1]: #ref-12

  跨膜蛋白16/anoctamin-1（ANO1）是一种在哺乳动物组织中广泛表达的蛋白质，具有经典钙激活氯通道（CaCC）的特性。这种蛋白质已被认为涉及许多主要的生理功能。然而，缺乏有效且选择性的阻断剂阻碍了对该通道生理功能的详细研究。在本研究中，我们利用先前建立的药物筛选方法（Oh等，2008），开发了一种对非洲爪蟾卵母细胞中内源性ANO1（xANO1）具有强效和选择性的阻断剂。我们合成了许多邻氨基苯甲酸衍生物，并确定了这些衍生物中的生物活性与取代基性质和位置之间的关联。从结构-活性关系中发现了一系列新的xANO1阻断剂化学类别。这些衍生物在萘基取代的邻氨基苯甲酸的5位含有一个−NO2基团，能完全阻断xANO1氯电流，IC50 < 10 μM。最强效的阻断剂，N -((4-甲氧基)-2-萘基)-5-硝基邻氨基苯甲酸（MONNA），对xANO1的IC50为0.08 μM。选择性测试表明，其他氯通道如bestrophin-1、氯通道蛋白2和囊性纤维化跨膜传导调节因子在10～30 μM MONNA下未被明显阻断。本研究识别出的对ANO1具有强效和选择性的阻断剂应能允许对ANO1/CaCC功能进行药理学解析，并作为治疗高血压、囊性纤维化、支气管炎、哮喘和痛觉过敏等相关疾病的潜在药物候选。
• Synthesis of Arylamides via Ritter-Type Cleavage of Solid-Supported Aryltriazenes
  作者：Nicolai A. Wippert、Nicole Jung、Stefan Bräse

  DOI：10.1021/acscombsci.9b00096

  日期：2019.8.12

  combined with an on-bead cross-coupling reaction of halogen-substituted aryltriazenes with pyrazoles. Additionally, the synthesis of on-bead generated arylboronic ester-substituted triazenes was shown. The developed procedure was further expanded to use other commercially available nitriles, such as acrylonitrile, benzonitrile, and chlorinated alkyl nitriles as suitable reagents for a Ritter-type cleavage

  提出了一种通过烷基或芳基腈裂解芳基三氮烯来合成N-芳基酰胺的新途径。我们开发了Ritter反应的一种变体，该变体允许在与固体负载前体的反应中使用乙腈作为溶剂和试剂。优化反应以生成N-芳基乙酰胺使用多种固定化的结构单元，包括邻，间和对位的芳基三氮烯。通过Ritter型转化的裂解与卤素取代的芳基三氮烯与吡唑的珠上交叉偶联反应结合。另外，显示了珠上生成的芳基硼酸酯取代的三氮烯的合成。进一步扩展了开发的程序，以使用其他可商购的腈，例如丙烯腈，苄腈和氯化烷基腈，作为用于制备的三氮烯连接基的Ritter型裂解的合适试剂。
• [EN] KRAS G12D INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12D
  申请人：MIRATI THERAPEUTICS INC

  公开号：WO2021041671A1

  公开（公告）日：2021-03-04

  The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及抑制KRas G12D的化合物。具体地，本发明涉及抑制KRas G12D活性的化合物，包括这些化合物的药物组合物以及使用方法。
• The Substituent Effect. X. Solvolysis of 3- and 4-Substituted 1-(1-Naphthylethyl) Chlorides
  作者：Yuho Tsuno、Masami Sawada、Takahiro Fujii、Yasuhide Yukawa

  DOI：10.1246/bcsj.48.3347

  日期：1975.11

  Fourteen 5-, 6-, and 7-substituted 1-(1-naphthylethyl) chlorides were prepared and the solvolysis rates were determined in 80% (v/v) aqueous acetone at 45 °C. The effects of −R substituents at respective positions were treated on the basis of the equation, logk⁄k0=ρiσi+ρx+σx+=ρ(Cijσi+qrij+σπ+). The position dependency of the inductive effect was given by Cij(=ρi⁄ρi,4α); C3α=1.37, C4α=1.00, C5α=0.75

  制备了 14 种 5-、6- 和 7-取代的 1-(1-萘基乙基) 氯化物，并在 45 °C 下在 80% (v/v) 丙酮水溶液中测定溶剂分解速率。各位置-R取代基的影响按等式处理，logk⁄k0=ρiσi+ρx+σx+=ρ(Cijσi+qrij+σπ+)。感应效应的位置依赖性由 Cij(=ρi⁄ρi,4α) 给出；C3α=1.37、C4α=1.00、C5α=0.75、C6α=0.57、C7α=0.72。Cij 值似乎与杜瓦的简化场函数 1/rij 相关。由比率 ρπ+⁄ρi,4α=qr·ij+ 给出的 Pi 电子效应的位置依赖性与 MO 指数的预测一致，例如 Forsyth 的 Δqij(ArCH2+ 参数。同样的处理也适用于其他三种萘反应性、脱氚、α-萘甲酸的 pKa 和萘基铵离子的 pKa。线性 ρi-ρi 关系在这些反应之间成立，表明感应传输的反应独立方案。qr·ij+ 值在共轭位置随
• [EN] COMPOSITIONS AND METHODS FOR INHIBITING BMP<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE LA BMP
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2016011019A1

  公开（公告）日：2016-01-21

  The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

  本发明提供了BMP信号通路的小分子抑制剂，以及用于抑制BMP信号通路的组合物和方法。这些化合物和组合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与BMP信号通路相关的疾病或症状，包括炎症、心血管疾病、血液疾病、癌症和骨骼疾病，以及用于调节细胞分化和/或增殖。这些化合物和组合物还可用于降低ApoB-100或LDL的循环水平，并治疗或预防获得性或先天性高胆固醇血症或高脂蛋白血症；与脂质吸收或代谢缺陷相关的疾病、紊乱或综合征；或由高脂血症引起的疾病、紊乱或综合征。